Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2′,3′-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5′-triphosphates

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 3, 2009, Pages 687-695

  Suryanarayana, Srividya ^a,e   Göttle, Martin ^b   Hübner, Melanie ^b   Gille, Andreas ^a,f   Mou, Tung Chung ^c   Sprang, Stephen R ^c   Richter, Mark ^a   Seifert, Roland ^d  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF MONTANA   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' O (2,4,6 TRINITROPHENYL)ADENOSINE 5' DIPHOSPHATE; 2',3' O (2,4,6 TRINITROPHENYL)ADENOSINE 5' MONOPHOSPHATE; 2',3' O (2,4,6 TRINITROPHENYL)ADENOSINE 5' TRIPHOSPHATE; 2',3' O (2,4,6 TRINITROPHENYL)CYTOSINE 5' TRIPHOSPHATE; 2',3' O (2,4,6 TRINITROPHENYL)GUANOSINE 5' DIPHOSPHATE; 2',3' O (2,4,6 TRINITROPHENYL)GUANOSINE 5' TRIPHOSPHATE; 2',3' O (2,4,6 TRINITROPHENYL)URACIL 5' TRIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; ADENYLATE CYCLASE I; ADENYLATE CYCLASE II; BENZENE DERIVATIVE; CYCLIC AMP; FLUORESCENT DYE; FORSKOLIN DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; GUANYLATE CYCLASE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ISOENZYME; NITRO DERIVATIVE; NUCLEOSIDE TRIPHOSPHATE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TRINITROPHENYL; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME MECHANISM; FLUORESCENCE SPECTROSCOPY; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; CELL MEMBRANE; CELLS, CULTURED; ENZYME INHIBITORS; FLUORESCENT DYES; GTP PHOSPHOHYDROLASES; GTP-BINDING PROTEINS; GUANYLATE CYCLASE; HUMANS; ISOENZYMES; MODELS, MOLECULAR; NUCLEOTIDES; PROTEIN BINDING; SIGNAL TRANSDUCTION; SPECTROMETRY, FLUORESCENCE;

EID: 70349092331     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.155432     Document Type: Article

References (38)

1. Ahuja N, Kumar P, and Bhatnagar R (2004) The adenylate cyclase toxins. Crit Rev Microbiol 30:187-196.
2. Chen Y, Cann MJ, Litvin TN, Iourgenko V, Sinclair ML, Levin LR, and Buck J (2000) Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. Science 289:625-628. (Pubitemid 30622067)
3. Defer N, Best-Belpomme M, and Hanoune J (2000) Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol 279:F400-F416.
4. Derbyshire ER and Marletta MA (2009) Biochemistry of soluble guanylate cyclase. Handb Exp Pharmacol 191:17-31.
5. Gille A, Guo J, Mou TC, Doughty MB, Lushington GH, and Seifert R (2005) Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5′-triphosphates, nucleoside 5′-[γ-thio]triphosphates and nucleoside 5′-[β,γ-imido]triphosphates. Biochem Pharmacol 71:89-97. (Pubitemid 41713530)
6. s proteins. J Biol Chem 277:34434-34442.
7. Gille A, Lushington GH, Mou TC, Doughty MB, Johnson RA, and Seifert R (2004) Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 279:19955-19969. (Pubitemid 38623438)
8. Gille A and Seifert R (2003a) 2′(3′)-O-(N-Methylanthraniloyl) -substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J Biol Chem 278:12672-12679. (Pubitemid 36800027)
9. s-proteins. Naunyn Schmiedebergs Arch Pharmacol 368:210-215.
10. Göttle M, Dove S, Steindel P, Shen Y, Tang WJ, Geduhn J, König B, and Seifert R (2007) Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides. Mol Pharmacol 72:526-535. (Pubitemid 47347287)
11. Göttle M, Geduhn J, König B, Gille A, Höcherl K, and Seifert R (2009) Characterization of mouse heart adenylyl cyclase. J Pharmacol Exp Ther 329:1156-1165.
12. Hiratsuka T (2003) Fluorescent and colored trinitrophenylated analogs of ATP and GTP. Eur J Biochem 270:3479-3485.
13. Hiratsuka T (1983) New ribose-modified fluorescent analogs of adenine and guanine nucleotides available as substrates for various enzymes. Biochim Biophys Acta 742:496-508.
14. Iwatsubo K, Minamisawa S, Tsunematsu T, Nakagome M, Toya Y, Tomlinson JE, Umemura S, Scarborough RM, Levy DE, and Ishikawa Y (2004) Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 279:40938-40945. (Pubitemid 39287693)
15. Jameson DM and Eccleston JF (1997) Fluorescent nucleotide analogs: synthesis and applications. Methods Enzymol 278:363-390. (Pubitemid 27229929)
16. Koesling D, Russwurm M, Mergia E, Mullershausen F, and Friebe A (2004) Nitric oxide-sensitive guanylyl cyclase: structure and regulation. Neurochem Int 45:813-819. (Pubitemid 39108053)
17. Laux WH, Pande P, Shoshani I, Gao J, Boudou-Vivet V, Gosselin G, and Johnson RA (2004) Pro-nucleotide inhibitors of adenylyl cyclase in intact cells. J Biol Chem 279:13317-13332. (Pubitemid 38468854)
18. sαS: consequences for receptor-coupling and adenylyl cyclase activation. J Neurochem 78:325-338.
19. Mou TC, Gille A, Fancy DA, Seifert R, and Sprang SR (2005) Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-triphosphate. J Biol Chem 280:7253-7261. (Pubitemid 40341283)
20. Mou TC, Gille A, Suryanarayana S, Richter M, Seifert R, and Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 2′,3′-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70:878-886. (Pubitemid 44268445)
21. Newton RP, Kingston EE, Hakeem NA, Salih SG, Beynon JH, and Moyse CD (1986) Extraction, purification, identification and metabolism of 3′,5′-cyclic UMP, 3′,5′-cyclic IMP and 3′,5′-cyclic dTMP from rat tissues. Biochem J 236:431-439.
22. Newton RP, Salih SG, Salvage BJ, and Kingston EE (1984) Extraction, purification and identification of cytidine 3′,5′-cyclic monophosphate from rat tissues. Biochem J 221:665-673.
23. Newton RP, Salvage BJ, and Hakeem NA (1990) Cytidylate cyclase: development of assay and determination of kinetic properties of a cytidine 3′,5′-cyclic monophosphate-synthesizing enzyme. Biochem J 265:581-586.
24. Pinto C, Hübner M, Gille A, Richter M, Mou TC, Sprang SR, and Seifert R (2009) Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogs. Biochem Pharmacol 78:62-69.
25. Pinto C, Papa D, Hübner M, Mou TC, Lushington GH, and Seifert R (2008) Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs. J Pharmacol Exp Ther 325:27-36.
26. Rottlaender D, Matthes J, Vatner SF, Seifert R, and Herzig S (2007) Functional adenylyl cyclase inhibition in murine cardiomyocytes by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-[γ-thio] triphosphate. J Pharmacol Exp Ther 321:608-615. (Pubitemid 46624491)
27. Schlicker C, Rauch A, Hess KC, Kachholz B, Levin LR, Buck J, and Steegborn C (2008) Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem 51:4456-4464.
28. Schmidt HH, Schmidt PM, and Stasch JP (2009) NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 191:309-339.
29. s interactions: evidence for multiple receptor conformations. Mol Pharmacol 56:348-358.
30. sα has properties of a constitutively active receptor. J Biol Chem 273:5109-5116.
31. Sunahara RK, Beuve A, Tesmer JJ, Sprang SR, Garbers DL, and Gilman AG (1998) Exchange of substrate and inhibitor specificities between adenylyl and guanylyl cyclases. J Biol Chem 273:16332-16338. (Pubitemid 28311412)
32. Sunahara RK and Taussig R (2002) Isoforms of mammalian adenylyl cyclase. Multiplicities of signaling. Mol Interv 2:168-184.
33. Taha HM, Schmidt J, Göttle M, Suryanarayana S, Shen Y, Tang WJ, Gille A, Geduhn J, König B, Dove S, et al. (2009) Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2′(3′)-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol Pharmacol 75:693-703.
34. Tesmer JJ, Dessauer CW, Sunahara RK, Murray LD, Johnson RA, Gilman AG, and Sprang SR (2000) Molecular basis for P-site inhibition of adenylyl cyclase. Biochemistry 39:14464-14471.
35. sα. Methods Enzymol 345:198-206.
36. sα-GTPγS. Science 278:1907-1916.
37. 3. J Biol Chem 274:33259-33266.
38. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, Hirotani S, Ishikawa Y, Sadoshima J, and Vatner SF (2007) Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130:247-258. (Pubitemid 47081133)